Abbott Laboratories

New York Stock Exchange
Back to all articles
Slightly Bullish +15

40,000 Shares in Abbott Laboratories $ABT Purchased by Canoe Financial LP

AI-generated analysis

📈 Canoe Financial LP acquired 40,000 shares of Abbott Laboratories ($ABT) in Q1, valued at approximately $4.1 million.

📉 American National Bank of Texas reduced its stake by 2.4% to 3,408 shares, while Park Place Capital Corp increased its position by 11.0%.

💰 Abbott Laboratories declared a quarterly dividend of $0.63 per share with an ex-dividend date of July 15th and a yield of 2.7%.

📊 The stock trades at a P/E ratio of 26.34 with a market cap of $163.77 billion and a debt-to-equity ratio of 0.56.

📉 Mizuho, Evercore, and Benchmark lowered their price targets to between $115 and $120, citing recent market conditions.

🔍 BTIG Research reaffirmed a 'buy' rating with a target price of $131.00, contrasting with the bearish moves from other analysts.

👤 CFO Philip P. Boudreau purchased 2,200 shares at an average cost of $91.50, demonstrating insider buying activity.

👤 Director Daniel J. Starks acquired 10,000 shares for a total transaction value of $926,500 in late April.

🏢 Abbott Laboratories operates through diagnostics, medical devices, nutritionals, and established pharmaceuticals globally.

📉 The stock opened at $94.02, trading below its 200-day simple moving average of $105.27.

Bullish Signals
  • Canoe Financial LP increased its stake in Abbott Laboratories by acquiring 40,000 shares worth approximately $4.1 million in the first quarter.
  • Park Place Capital Corp grew its position by 11.0% to own 815 shares valued at $102,000 during the fourth quarter.
  • Clayton Financial Group LLC lifted its stake by 1.4% to own 6,217 shares worth $779,000 in the fourth quarter.
  • CFO Philip P. Boudreau purchased 2,200 shares of company stock for a total value of $201,300 in April.
  • Director Daniel J. Starks bought 10,000 shares at an average cost of $92.65 per share, increasing his direct ownership by 0.15%.
  • BTIG Research reaffirmed a 'buy' rating with a target price of $131.00, indicating continued analyst confidence in the stock.
Risk Factors
  • Mizuho dropped its target price on Abbott Laboratories from $125.00 to $115.00 and set a 'neutral' rating.
  • Evercore lowered their price objective from $134.00 to $120.00 despite maintaining an 'outperform' rating.
  • Benchmark reduced their target price on Abbott Laboratories from $145.00 to $120.00 in a recent report.
  • Royal Bank Of Canada decreased their price target from $135.00 to $130.00 while setting an 'outperform' rating.
  • The stock opened at $94.02, trading below its 200-day simple moving average of $105.27.
Full Analysis
Abbott Laboratories (NYSE: ABT) saw institutional investor Canoe Financial LP acquire a new stake of 40,000 shares in the first quarter, valued at approximately $4.1 million, according to recent SEC 13F filings. Several other hedge funds adjusted their positions during the same period, with American National Bank of Texas reducing holdings by 2.4% while Park Place Capital Corp and Clayton Financial Group LLC increased theirs by 11.0% and 1.4%, respectively. Institutional ownership remains high at 75.18%. The company's stock opened at $94.02, trading below its 200-day moving average of $105.27 but above its 50-day average of $89.08. Key financial metrics include a market capitalization of $163.77 billion, a P/E ratio of 26.34, and a debt-to-equity ratio of 0.56. Abbott recently declared a quarterly dividend of $0.63 per share, payable on August 17th to shareholders of record on July 15th, representing an annualized yield of 2.7%. Analyst sentiment is mixed with recent target price adjustments from major firms like Mizuho, Evercore, and Benchmark lowering their objectives to around $115-$120, though BTIG maintains a buy rating at $131. The consensus rating is 'Moderate Buy' with an average target price of $118.30. Notably, CFO Philip P. Boudreau purchased 2,200 shares and Director Daniel J. Starks bought 10,000 shares in April, signaling insider confidence.